Journals / Viral Hepatitis Journal / 2015 / Cilt: 21 - Sayı: 3

Akut Karaciğer Yetmezliğinin Tedavisinde Plazmaferez: Olgu Sunumu ve Literatür İncelemesi

Plasmapheresis in the Treatment of Acute Liver Failure: A Case Report and a Review of the Literature

Pages
98–101
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Plasmapheresis can be thought as treatment for patients in whom liver transplantation is not an option or for patients pending transplantation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Acute liver failure (ALF) is a fatal and challenging disease even for patients without underlying diseases.
📊
Key Findings & Data:A 36-year-old male with sickle-cell anemia (SCA) and G6PD deficiency presented with jaundice and fever.
💡
Conclusion & Impact:Plasmapheresis can be thought as treatment for patients in whom liver transplantation is not an option or for patients pending transplantation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Acute liver failure (ALF) is a fatal and challenging disease even for patients without underlying diseases. In this paper, we aimed to share our opinion about a treatment option for cholestatic fulminant hepatitis where transplantation is not an option. A 36-year-old male with sickle-cell anemia (SCA) and G6PD deficiency presented with jaundice and fever. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, direct bilirubin and international normalized ratio (INR) levels were 335 mg/dl, 430 mg/dl, 30 mg/dl, 18 mg/dl and 1.2, respectively at the admission. HBsAg was positive. Hepatitis B virus (HBV) DNA was 64.000.000 IU/ml. On the third week of admission, ALT, AST, total bilirubin and direct bilirubin levels increased up to 270 mg/dl, 460 mg/dl, 71 mg/dl and 47 mg/dl, respectively. INR prolongation accompanied. Hepatic encephalopathy developed. Entecavir 1x1 mg and fresh frozen plasma was started. The condition of the patient continued to deteriorate and, MELD score was 38. After two sessions of plasmapheresis, ALT, AST, total bilirubin, direct bilirubin and INR levels decreased to 30 mg/dl, 90 mg/dl, 9 mg/dl, 4 mg/dl, 1.2, respectively. The patient was discharged eventually. Plasmapheresis can be thought as treatment for patients in whom liver transplantation is not an option or for patients pending transplantation.

Özet

Akut karaciğer yetmezliği (AKY) altta yatan hastalığı olmayan kişilerde bile oldukça zor yönetilen bir ölümcül durumdur. Bu olguda, transplantasyonun bir seçenek olmadığı kolestatik fulminant hepatit için tedavi önerisini paylaşmak istedik. Otuz altı yaşında orak hücreli anemisi (OHA) ve glukoz 6 fosfat eksikliği olan bir hasta sarılık ve ateş ile başvurdu. Yatış sırasında, alanin aminotransferaz (ALT), aspartat aminotransferaz (AST), total bilirubin, direk bilirubin ve INR seviyeleri 335 mg/dl, 430 mg/dl, 30 mg/dl, 18 mg/dl ve 1,2 idi. HBsAg pozitif ve HBV DNA 64.000.000 IU/ml idi. Üçüncü haftada ALT, AST, total bilirubin ve direk bilirubin seviyeleri yükselerek 270 mg/dl, 460 mg/dl, 71 mg/dl ve 47 mg/dl oldu. Uluslararası normalleştirilmiş oran (UNO) uzaması eşlik etti ve ensefalopati gelişti. Entekavir 1x1 mg ve taze donmuş plazma tedavisi başlandı. Hasta kötüleşmeye devam etti ve MELD skoru 38 olarak hesaplandı. Iki kez plazmaferez uygulanması sonrasında ALT, AST, total bilirubin, direk bilirubin ve UNO seviyeleri 30 mg/dl, 90 mg/dl, 9 mg/dl, 4 mg/dl, 1,2'ye düştü. Genel durumu düzelen hasta taburcu edildi. Karaciğer transplantasyonunun tedavi seçeneği olmadığı hastalarda veya transplantasyon beklenen durumlarda plazmaferez tedavide düşünülebilir.

🔖

Cite This Article

ULU, A. C., KURAN, S., KURTARAN, B., İNAL, A. S., KÖMÜR, S., TEKİNTURHAN, F., GÜVENÇ, B., AKSU, H. S. Z. (2015). Akut Karaciğer Yetmezliğinin Tedavisinde Plazmaferez: Olgu Sunumu ve Literatür İncelemesi. Viral Hepatitis Journal, Cilt: 21 - Sayı: 3, 98–101. https://ajindex.com/articles/332686

References (11)

  1. Ocak S, Kaya H, Cetin M, Gali E, Ozturk M. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. Arch Med Res. 2006;37(7):895-898. Schubert TT. Hepatobiliary system in sickle cell disease. Gastroenterology. 1986;90(6):2013-2021.
  2. Eisenhuber E, Madl C, Kramer L, Steininger R, Yeganehfar W, Ratheiser K, Gangl A. Prognostic factors in acute liver failure. Wien Klin Wochenschr. 1998;110(16):564-569. Bacher A. Extracorporeal liver support with multipass albumin dialysis or plasmapheresis and filtering systems in acute liver failure. Liver Int. 2011;31 Suppl 3:16-18.
  3. Banerjee S, Owen C, Chopra S. Sickle cell hepatopathy. Hepatology. 2001;33(5):1021-1028.
  4. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134(6):1764-1776.
  5. Blinder MA, Geng B, Lisker-Melman M, Crippin JS, Korenblat K, Chapman W, Shenoy S, Field JJ. Successful orthotopic liver transplantation in an adult patient with sickle cell disease and review of the literature. Hematol Rep. 2013;5(1):1-4.
  6. Dao DY, Seremba E, Ajmera V, Sanders C, Hynan LS, Lee WM; Acute Liver Failure Study Group. Use of nucleoside (tide) analogues in patients with hepatitis B-related acute liver failure. Dig Dis Sci. 2012;57(5):1349-1357.
  7. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns MP. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13(4):256-263.
  8. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, Zuckerman E, Sbeit W, Ackerman Z, Safadi R, Lurie Y, Rosner G, Tur-Kaspa R, Reshef R. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int. 2004;24:547-551.
  9. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on- chronic liver failure. Clin Exp Med. 2012;12(3):159-164. 101 Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-662.
  10. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150(2):104-110.
  11. Place E, Wenzel JE, Arumugam R, Belani K, Messinger Y.